ANIX Anixa Biosciences
- 2.950
- -0.020-0.67%
Anixa Biosciences News
Anixa Biosciences Enters JV With Cleveland Clinic for Additional Cancer Vaccines
Anixa Biosciences Forms Cancer Vaccine Partnership With Cleveland Clinic
Anixa Biosciences Partners With Cleveland Clinic To Develop Cancer Vaccines
Anixa Biosciences Partners With Cleveland Clinic To Develop Cancer Vaccines
Anixa Biosciences Expands Partnership With Cleveland Clinic to Develop Additional Cancer Vaccines
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX
Anixa Biosciences 13D Filing Shows President, COO & CFO Michael Catelani Reported A 5.25% Stake In The Co As Of April 30, 2024
Anixa Biosciences 13D Filing Shows President, COO & CFO Michael Catelani Reported A 5.25% Stake In The Co As Of April 30, 2024
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to Its Cancer Business Advisory Board
Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations.
Anixa Biosciences(ANIX.US) Director Buys US$49,229.52 in Common Stock
$Anixa Biosciences(ANIX.US)$ Director Titterton Lewis H jr purchased 15,009 shares of common stock on Apr 9, 2024 at an average price of $3.28 for a total value of $49,229.52.Source: Announcement What
Anixa Biosciences Stockholders Affirm Confidence and Oversight
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
Anixa Biosciences(ANIX.US) Director Buys US$36,300 in Common Stocks
$Anixa Biosciences(ANIX.US)$ Director Baskies Arnold M purchased 10,000 shares of Common Stocks on Mar 15, 2024 at an average price of $3.63 for a total value of $36,300.Source: Announcement What is s
Anixa Biosciences(ANIX.US) Officer Buys US$96,600 in Common Stocks
$Anixa Biosciences(ANIX.US)$ Officer KUMAR AMIT purchased 30,000 shares of Common Stocks on Mar 15, 2024 at an average price of $3.22 for a total value of $96,600.Source: Announcement What is statemen
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
SAN JOSE, Calif., March 14, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of c
Recap: Anixa Biosciences Q1 Earnings
Anixa Biosciences (NASDAQ:ANIX) reported its Q1 earnings results on Tuesday, March 12, 2024 at 05:00 PM.Here's what investors need to know about the announcement.EarningsAnixa Biosciences missed estim
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Analysts Conflicted on These Healthcare Names: Anixa Biosciences (ANIX) and InMode (INMD)
Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment
Anixa Biosciences (ANIX) said Monday it started treatment of the fourth patient in its phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. The fourth patie
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of...
Analysis
Price Target
No Data
